Table 1 Baseline characteristics
Number of patients | n = 11 |
|---|---|
Age, years | 67.2 ± 12.2 |
Male, n (%) | 3 (27.3) |
BMI, kg/m2 | 22.4 ± 2.5 |
NYHA class III or IV, n (%) | 7 (63.6) |
Syncope, n (%) | 1 (9.1) |
Hypertension, n (%) | 4 (36.4) |
Diabetes mellitus, n (%) | 0 (0.0) |
Dyslipidemia, n (%) | 4 (36.4) |
COPD, n (%) | 0 (0.0) |
Current smoking, n (%) | 0 (0.0) |
CPA, n (%) | 0 (0.0) |
Stroke, n (%) | 0 (0.0) |
Atrial fibrillation, n (%) | 2 (18.2) |
CIED implantation, n (%) | 0 (0.0) |
Family history of SCD, n (%) | 1 (9.1) |
Family history of HCM, n (%) | 3 (27.3) |
Medication | Â |
 Na channel blockers, n (%) | 8 (72.7) |
 Beta blockers, n (%) | 10 (90.9) |
 Calcium channel antagonists, n (%) | 7 (63.6) |
 ACE-Is/ARBs, n (%) | 1 (9.1) |
 Amiodarones, n (%) | 1 (9.1) |
 OACs, n (%) | 2 (18.2) |
Laboratory data | Â |
 NT-proBNP, pg/mL | 1610.5 (211.0–5060.0) |
Echocardiographic variables | Â |
 LVEDD, mm | 41.4 ± 4.0 |
 LVESD, mm | 24.6 ± 3.8 |
 Max-IVST, mm | 17.6 ± 4.4 |
 LAD, mm | 40.5 ± 5.1 |
 LAVI, mL/m2 | 58.8 ± 16.9 |
 Resting LVOT PPG, mmHg | 108.7 ± 68.8 |
 Moderate or severe MR, n (%) | 7 (63.6) |
 Anterior leaflet length of MV, mm | 25.9 ± 4.7 |
 Posterior leaflet length of MV, mm | 17.4 ± 4.0 |
 SAM grade of MV |  |
 G0, n (%) | 1 (9.1) |
 G1, n (%) | 0 (0.0) |
 G2, n (%) | 1 (9.1) |
 G3, n (%) | 5 (45.4) |
 G4, n (%) | 4 (36.3) |